Dostarlimab: A Review of Its Pharmacology and Clinical Use in Management of Cancer
Busayo Odunayo Akodu, Azike Ruth Chinazor, Ikalo David Oseghale, Regina Titilayo Oddiri, George Chigozie Njoku, Godwin Okoye
International Research Journal of Oncology · pp. 108–113 · Published 11 Oct 2022
Abstract
According to the World Health Organization, cancer is the biggest cause of mortality globally, accounting for almost 10 million deaths in 2020, or nearly one in every six deaths (WHO). Breast (2.26 million instances), lung (2.21 million cases), colon and rectum (1.93 million cases), and prostate cancers will be the most frequent cancers in 2020 (1.41 million Cases). A PD-1 monoclonal antibody called dostarlimab (JEMPERLI) has been found to be effective in treatment of patients with rectal cancer, who have advanced or recurrent disease that is mismatch repair deficient (dMMR) and who have progressed during or after prior treatment with a platinum-containing regimen. This indication was quickly approved based on the rate of tumor response and the length of the response, both of which were determined using an FDA-approved test. In this review, we provide simple and comprehensible pharmacodynamic and Pharmacokinetic details of the drug to the healthcare community as we believe it would serve as quick point of reference in cases of emergency information search.
Cited by 0
No indexed citations yet.
Related research
- Does Pain Adversely Affect the Quality of Life in Hospitalized Cancer Patients? — shares topic coverage
- Complementary Medicine Intervention in Breast Cancer Patients with Pain — shares topic coverage
- Use of Performance Status Score for Cytotoxic Chemotherapy among Surgeons in a Tertiary Hospital, Southern Nigeria — shares topic coverage
- Breast Self Examination and Cancer Awareness among Female Staff in Federal Medical Center, Yenagoa, Bayelsa State (Knowledge and Practice) — shares topic coverage
- Assessment of Cancer Risk from Fluorscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.